Seelos Therapeutics Inc SEEL

NAS: SEEL | ISIN: US81577F1093   1/05/2024
0,300 USD (+7,53%)
(+7,53%)   1/05/2024

29 april 2024 · Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations · Persbericht

19 maart 2024 · Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose) · Persbericht

26 januari 2024 · Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules · Persbericht

22 januari 2024 · Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002 · Persbericht

2 januari 2024 · Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024 · Persbericht

22 december 2023 · Seelos Therapeutics, Inc. Releases Letter to its Stockholders · Persbericht

1 december 2023 · Seelos Therapeutics Announces Closing of Public Offering · Persbericht

27 oktober 2023 · Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023 · Persbericht

17 oktober 2023 · Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations · Persbericht

28 september 2023 · Thinking about buying stock in Oncolytics Biotech, Near Intelligence, Basin Uranium, Seelos Therapeutics, or MillerKnoll? · Persbericht

28 september 2023 · Thinking about buying stock in Seelos Therapeutics, West Red Lake Gold Mines, Immunovant, MSP Recovery, or Transcode Therapeutics? · Persbericht

27 september 2023 · Thinking about buying stock in American Lithium, Avalo Therapeutics, Seelos Therapeutics, Rivian Automotive, or Immunovant? · Persbericht

27 september 2023 · Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease · Persbericht

21 september 2023 · Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock · Persbericht

20 september 2023 · Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide · Persbericht

14 augustus 2023 · Seelos Therapeutics Provides Second Quarter 2023 Clinical Update · Persbericht

22 juni 2023 · Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD) · Persbericht

22 mei 2023 · Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences · Persbericht

15 mei 2023 · Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results · Persbericht

5 mei 2023 · Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting · Persbericht

Mijn selecties